KPV: Three Residues Cut From the End of a Hormone

Abstract, in plain English

The body makes a hormone called alpha-MSH — alpha-melanocyte-stimulating hormone. It is thirteen amino acids long, and it does two quite separate things: it drives pigment production in skin, and it calms inflammation.

KPV is the last three of those thirteen amino acids, on their own: lysine, proline, valine. Nothing has been added or altered. It is a piece of a human hormone, sold as a compound in its own right.

The interesting part is what the piece does. In laboratory and animal studies it keeps the parent hormone's anti-inflammatory effect and loses the pigment effect — which is precisely why researchers became interested in it. It also appears to work through a different route than the whole hormone: it slips into gut cells through a transporter that only accepts very short peptides, a door the thirteen-residue hormone is too large to use.

One fact frames everything below. No human clinical trial of KPV has ever been published. Every efficacy result on this page comes from cells in a dish or from mice.

What it is

KPV is the linear tripeptide L-lysyl-L-prolyl-L-valine, molecular formula C16H30N4O4, corresponding to residues 11 to 13 — the C-terminal sequence — of alpha-melanocyte-stimulating hormone. The literature also refers to it as alpha-MSH(11-13) or simply Lys-Pro-Val.

It is worth being precise about what "endogenous" means in this case. The tripeptide is not a hormone the body secretes as such; it is a segment of one. Whether the sequence circulates as a free fragment after natural proteolysis of alpha-MSH is a separate question from whether the sequence exists inside a human protein, and only the latter is firmly established. A vial of KPV is a synthesised copy of part of a molecule, presented to tissue without the other ten residues that normally accompany it and without the regulated release that governs the parent hormone.

Regulatory position: KPV is not an approved drug or dietary supplement in any major jurisdiction. It is sold by chemical suppliers for laboratory research use only, and no validated human dosing or clinical safety data exists.

How it works

In research models KPV dampens inflammation chiefly by suppressing NF-kB and MAP-kinase signalling — two of the central control systems a cell uses to decide how loudly to respond to an inflammatory stimulus — and by reducing production of pro-inflammatory cytokines including IL-1beta and TNF-alpha ^[8].

The delivery route is where the fragment diverges most sharply from its parent. In the gut, KPV is taken directly into epithelial cells by PepT1 (SLC15A1), a transporter that carries di- and tripeptides only, and which is upregulated in inflamed intestinal tissue ^[8]. A thirteen-residue hormone cannot use that transporter. The fragment therefore reaches an intracellular compartment by a route the whole molecule has no access to, and it does so preferentially in tissue that is already inflamed — the transporter's own upregulation acts as a crude targeting mechanism.

The receptor question is the sharper one. Alpha-MSH acts through melanocortin receptors. KPV, in the published dissections, largely does not. Its anti-inflammatory activity was retained in mice lacking MC1R ^[9], and a receptor-level analysis concluded the C-terminal tripeptide is unlikely to act through melanocortin receptors at all, proposing inhibition of IL-1beta function as the more probable mechanism ^[12]. The same study found KPV reduced polymorphonuclear leukocyte accumulation without suppressing macrophage cytokine release, unlike the core MSH peptides — a mechanistically distinct action, not a weaker version of the same one.

What the research shows

The evidence base is preclinical, consistent within its own limits, and concentrated in models of intestinal inflammation.

In human intestinal epithelial cell lines and Jurkat T cells, nanomolar KPV reduced NF-kB and MAPK activation and pro-inflammatory cytokine secretion; in C57BL/6 mice, oral KPV reduced the severity of both DSS- and TNBS-induced colitis ^[8]. A separate murine programme using DSS-induced and CD45RB-hi adoptive-transfer colitis reported earlier recovery and significantly stronger regain of body weight in KPV-treated animals, with reduced colonic inflammatory infiltrate and lower myeloperoxidase activity — and, critically, retained activity in MC1R-deficient mice ^[9].

Most recent work is formulation engineering rather than new biology, because the free tripeptide does not survive long enough to be useful. Orally administered hyaluronic-acid-functionalised nanoparticles carrying KPV, embedded in a chitosan/alginate hydrogel, delivered the peptide to inflamed colon tissue and prevented mucosal damage and downregulated TNF-alpha more effectively than non-targeted formulations in DSS colitis ^[7]. A 2024 PepT1-targeted nanodrug co-assembling KPV with the immunosuppressant FK506 improved both acute (4% DSS) and chronic (2.5% DSS) colitis in mice, restoring tight-junction proteins and lowering inflammatory cytokines beyond either agent alone ^[6].

Outside the gut, topical alpha-MSH(11-13) accelerated corneal epithelial wound healing in rabbits through a nitric-oxide-dependent mechanism: by 60 hours, 8 of 8 KPV-treated corneas were completely re-epithelialised versus none of the placebo-treated corneas (P<0.05) ^[11].

A comprehensive review of alpha-MSH and its related tripeptides places KPV as the anti-inflammatory alternative to the full hormone — protective across fever, dermatitis, vasculitis, fibrosis, ocular, gastrointestinal, brain, airway, arthritic and organ-injury models, while lacking the parent's pigmentary action ^[10].

Documented concerns and safety context

No compiled set of community-reported effects accompanies this entry, so nothing anecdotal is presented for KPV on this page. The concerns below are the ones the published literature itself raises.

The first is the absence of human data. No published human clinical trial of KPV exists, so human efficacy and human safety are both unestablished — not disputed, not weakly supported, simply not studied. Marketing of KPV for gut health, skin or general anti-inflammatory use runs well ahead of a literature that is mechanistic and preclinical.

The second is stability. Free KPV is a small, peptidase-labile tripeptide with no validated human pharmacokinetics, which is why so much recent effort goes into nanoparticle and hydrogel carriers ^[7][6] rather than into the peptide itself. Findings obtained with a targeted carrier do not transfer automatically to free peptide taken by another route.

The third is a naming problem with practical consequences. KPV derives from alpha-MSH, and alpha-MSH analogues include agents used for pigmentation and tanning; the defining feature of KPV in the literature is anti-inflammatory action without pigmentary effect ^[10], and conflating the two misrepresents both. Finally, incorrect study identifiers are common in secondary web sources for KPV — this corpus re-verified every identifier at source, and citations for this compound are best checked against the original record rather than copied from aggregators.

Where it fits in these origins

KPV is the cleanest counter-example to the assumption that a fragment behaves like a smaller dose of its parent.

Nothing was modified. The three residues are exactly the residues that terminate alpha-MSH, in exactly that order. If provenance determined pharmacology, KPV would be a mild, short-acting alpha-MSH. Instead it drops one of the parent hormone's two headline effects entirely ^[10], keeps working when the parent's principal receptor is absent ^[9], probably acts through a different mechanism altogether ^[12], and enters cells through a transporter the parent cannot use ^[8].

Subtraction, in other words, is a chemical modification with pharmacological consequences, even though nothing was added. The same argument runs in the other direction on the page for PT-141, which is drawn from the middle of the very same hormone and is deliberately engineered rather than merely cut — two compounds, one parent molecule, and almost nothing in common downstream.

What the origin story buys KPV is a plausible starting hypothesis and a reason its anti-inflammatory activity was looked for in the first place. What it does not buy is human evidence, and on that count the ledger for KPV is empty.